The immunology of human cytomegalovirus latency: Could latent infection be cleared by novel immunotherapeutic strategies?

Cellular and Molecular Immunology

Volumn 12, Issue 2, 2015, Pages 128-138

  Wills, Mark R ^a   Poole, Emma ^a   Lau, Betty ^a   Krishna, Ben ^a   Sinclair, John H ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cytomegalovirus; immune evasion; immunotherapeutic; latency

Indexed keywords

CELL PROTEIN; MICRORNA; SECRETOME; UNCLASSIFIED DRUG; VIRUS PROTEIN;

CELLULAR SECRETION; CYTOMEGALOVIRUS INFECTION; GENE EXPRESSION; GENE INDUCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LATENT VIRUS INFECTION; MOLECULAR BIOLOGY; NONHUMAN; ORGAN TRANSPLANTATION; PREGNANCY; PRIMARY INFECTION; REVIEW; T LYMPHOCYTE; VERTICAL TRANSMISSION; VIRAL CLEARANCE; VIRUS GENE; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS TRANSCRIPTION; ANIMAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; IMMUNOLOGY; VIROLOGY; VIRUS ACTIVATION;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

ANIMALS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOTHERAPY; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84929960117     PISSN: 16727681     EISSN: 20420226     Source Type: Journal    
DOI: 10.1038/cmi.2014.75     Document Type: Review

References (97)

1. Rubin RH. Cytomegalovirus in solid organ transplantation. Transpl Infect Dis 2001; 3(Suppl 2): 1-5.
2. Sinclair J, Sissons P. Latency and reactivation of human cytomegalovirus. J Gen Virol 2006; 87: 1763-1779.
3. Jackson SE, Mason GM, Wills MR. Human cytomegalovirus immunity and immune evasion. Virus Res 2011; 157: 151-160.
4. Powers C, DeFilippis V, Malouli D, Fruh K. Cytomegalovirus immune evasion. Curr Top Microbiol Immunol 2008; 325: 333-359.
5. Amsler L, Verweij MC, DeFilippis VR. The tiers and dimensions of evasion of the type I interferon response by human cytomegalovirus. J Mol Biol 2013; 425: 4857-4871.
6. McSharry BP, Avdic S, Slobedman B. Human cytomegalovirus encoded homologs of cytokines, chemokines and their receptors: roles in immunomodulation. Viruses 2012; 4: 2448-2470.
7. Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prodhomme V, Aicheler R et al. Modulation of natural killer cells by human cytomegalovirus. J Clin Virol 2008; 41: 206-212.
8. Sinclair J. Manipulation of dendritic cell functions by human cytomegalovirus. Expert Rev Mol Med 2008; 10: e35.
9. Sinclair J. Human cytomegalovirus: latency and reactivation in the myeloid lineage. J Clin Virol 2008; 41: 180-185.
10. Sinclair JH, Reeves MB. Human cytomegalovirus manipulation of latently infected cells. Viruses 2013; 5: 2803-2824.
11. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009; 22: 76-98, Table of Contents.
12. BrittWJ,MachM. Human cytomegalovirus glycoproteins. Intervirology 1996; 39: 401-412.
13. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 2010; 84: 1005-1013.
14. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F et al. Broadly targeted human cytomegalovirus-specific CD41 and CD81 T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202: 673-685.
15. Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett 2014; 342: 1-8.
16. Kowalsky S, Arnon R, Posada R. Prevention of cytomegalovirus following solid organ transplantation: a literature review. Pediatr Transplant 2013; 17: 499-509.
17. Schleiss MR. Cytomegalovirus in the neonate: immune correlates of infection and protection. Clin Dev Immunol 2013; 2013: 501801.
18. Griffiths P, Plotkin S, Mocarski E, Pass R, Schleiss M, Krause P et al. Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine 2013; 31(Suppl 2): B197-B203.
19. Tu W, Chen S, Sharp M, Dekker C, Manganello AM, Tongson EC et al. Persistent and selective deficiency of CD41 T cell immunity to cytomegalovirus in immunocompetent young children. J Immunol 2004; 172: 3260-3267.
20. Cheung AK, Gottlieb DJ, Plachter B, Pepperl-Klindworth S, Avdic S, Cunningham AL et al. The role of the human cytomegalovirus UL111A gene in down-regulating CD41 T-cell recognition of latently infected cells: implications for virus elimination during latency. Blood 2009; 114: 4128-4137.
21. Stern JL, Slobedman B. Human cytomegalovirus latent infection of myeloid cells directs monocyte migration by up-regulating monocyte chemotactic protein-1. J Immunol 2008; 180: 6577-6585.
22. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest 2000; 117: 1162-1172.
23. Reddehase MJ. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol 2002; 2: 831-844.
24. Moutaftsi M, Mehl AM, Borysiewicz LK, Tabi Z. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood 2002; 99: 2913-2921.
25. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol 1991; 72(Pt 9): 2059-2064.
26. Mendelson M, Monard S, Sissons P, Sinclair J. Detection of endogenous human cytomegalovirus in CD341 bone marrow progenitors. J Gen Virol 1996; 77: 3099-3102.
27. Sindre H, Tjoonnfjord GE, Rollag H, Ranneberg-Nilsen T, Veiby OP, Beck S et al. Human cytomegalovirus suppression of and latency in early hematopoietic progenitor cells. Blood 1996; 88: 4526-4533.
28. Poole E, Walther A, Raven K, Benedict CA, Mason GM, Sinclair J. The myeloid transcription factor GATA-2 regulates the viral UL144 gene during human cytomegalovirus latency in an isolate-specific manner. J Virol 2013; 87: 4261-271.
29. Rossetto CC, Tarrant-Elorza M, Pari GS. Cis and trans acting factors involved in human cytomegalovirus experimental and natural latent infection of CD141 monocytes and CD341 cells. PLoS Pathog 2013; 9: e1003366.
30. Reeves MB, Lehner PJ, Sissons JG, Sinclair JH. An in vitro model for the regulation of human cytomegalovirus latency and reactivation in dendritic cells by chromatin remodelling. J Gen Virol 2005; 86: 2949-2954.
31. Kondo K, Kaneshima H, Mocarski ES. Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc Natl Acad Sci USA 1994; 91: 11879-11883.
32. Hahn G, Jores R, Mocarski ES. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci USA 1998; 95: 3937-3942.
33. Avdic S, Cao JZ, Cheung AK, Abendroth A, Slobedman B. Viral interleukin-10 expressed by human cytomegalovirus during the latent phase of infection modulates latently infected myeloid cell differentiation. J Virol 2011; 85: 7465-7471.
34. Bego M, Maciejewski J, Khaiboullina S, Pari G, St Jeor S. Characterization of an antisense transcript spanning the UL81-82 locus of human cytomegalovirus. J Virol 2005; 79: 11022-11034.
35. Goodrum F, Reeves M, Sinclair J, High K, Shenk T. Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood 2007; 110: 937-945.
36. Hargett D, Shenk TE. Experimental human cytomegalovirus latency in CD141monocytes. Proc Natl Acad Sci USA 2010; 107: 20039-20044.
37. Reeves MB, Sinclair JH. Analysis of latent viral gene expression in natural and experimental latency models of human cytomegalovirus and its correlation with histone modifications at a latent promoter. J Gen Virol 2010; 91: 599-604.
38. Taylor-Wiedeman J, Sissons P, Sinclair J. Induction of endogenous human cytomegalovirus gene expression after differentiation of monocytes from healthy carriers. J Virol 1994; 68: 1597-1604.
39. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997; 91: 119-126.
40. Reeves MB, MacAry PA, Lehner PJ, Sissons JG, Sinclair JH. Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc Natl Acad Sci USA 2005; 102: 4140-4145.
41. Stenberg RM. The human cytomegalovirus major immediate-early gene. Intervirology 1996; 39: 343-349.
42. Spector DH. Activation and regulation of human cytomegalovirus early genes. Intervirology 1996; 39: 361-377.
43. Colberg-Poley AM. Functional roles of immediate early proteins encoded by the human cytomegalovirus UL36-38, UL115-119, TRS1/IRS1 and US3 loci. Intervirology 1996; 39: 350-360.
44. Gatherer D, Seirafian S, Cunningham C, Holton M, Dargan DJ, Baluchova K et al. High-resolution human cytomegalovirus transcriptome. Proc Natl Acad Sci USA 2011; 108: 19755-19760.
45. Cheung AK, Abendroth A, Cunningham AL, Slobedman B. Viral gene expression during the establishment of human cytomegalovirus latent infection in myeloid progenitor cells. Blood 2006; 108: 3691-3699.
46. Goodrum FD, Jordan CT, High K, Shenk T. Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency. Proc Natl Acad Sci USA 2002; 99: 16255-16260.
47. Poole E, Wills M, Sinclair J. Human cytomegalovirus latency: targeting differences in the latently infected cell with a view to clearing latent infection. New J Sci 2014; 2014: 313761.
48. Albright ER, Kalejta RF. Myeloblastic cell lines mimic some but not all aspects of human cytomegalovirus experimental latency defined in primary CD341 cell populations. J Virol 2013; 87: 9802-9812.
49. Beisser PS, Laurent L, Virelizier JL, Michelson S. Human cytomegalovirus chemokine receptor gene US28 is transcribed in latently infected THP-1 monocytes. J Virol 2001; 75: 5949-5957.
50. Hook L, Hancock M, Landais I, Grabski R, Britt W, Nelson JA. Cytomegalovirus microRNAs. Curr Opin Virol 2014; 7C: 40-6.
51. Grey F, Meyers H, White EA, Spector DH, Nelson J. A human cytomegalovirus-encoded microRNA regulates expression of multiple viral genes involved in replication. PLoS Pathog 2007; 3: e163.
52. Murphy E, Vanicek J, Robins H, Shenk T, Levine AJ. Suppression of immediate-early viral gene expression by herpesvirus-coded microRNAs: implications for latency. Proc Natl Acad Sci USA 2008; 105: 5453-5458.
53. Stern-Ginossar N, Saleh N, Goldberg MD, Prichard M, Wolf DG, Mandelboim O. Analysis of human cytomegalovirus-encoded microRNA activity during infection. J Virol 2009; 83: 10684-10693.
54. Stern-Ginossar N, Elefant N, Zimmermann A, Wolf DG, Saleh N, Biton Met al. Host immune system gene targeting by a viral miRNA. Science 2007; 317: 376-381.
55. Kim S, Lee S, Shin J, Kim Y, Evnouchidou I, Kim D et al. Human cytomegalovirus microRNA miR-US4-1 inhibits CD81 T cell responses by targeting the aminopeptidase ERAP1. Nat Immunol 2011; 12: 984-991.
56. Kim Y, Lee S, Kim S, Kim D, Ahn JH, Ahn K. Human cytomegalovirus clinical strain-specific microRNA miR-UL148D targets the human chemokine RANTES during infection. PLoS Pathog 2012; 8: e1002577.
57. Shen ZZ, Pan X, Miao LF, Ye HQ, Chavanas S, Davrinche C et al. Comprehensive analysis of human cytomegalovirus microRNA expression during lytic and quiescent infection. PloS One 2014; 9: e88531.
58. Fu M, Gao Y, Zhou Q, Zhang Q, Peng Y, Tian K et al. Human cytomegalovirus latent infection alters the expression of cellular and viral microRNA. Gene 2014; 536: 272-278.
59. Maciejewski JP, Bruening EE, Donahue RE, Mocarski ES, Young NS, St Jeor SC. Infection of hematopoietic progenitor cells by human cytomegalovirus. Blood 1992; 80: 170-178.
60. Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES, Spaete RR. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 1996; 70: 78-83.
61. Mason GM, Poole E, Sissons JG, Wills MR, Sinclair JH. Human cytomegalovirus latency alters the cellular secretome, inducing cluster of differentiation CD41 T-cell migration and suppression of effector function. Proc Natl Acad Sci USA 2012; 109: 14538-14543.
62. Poole E, McGregor Dallas SR, Colston J, Joseph RS, Sinclair J. Virally induced changes in cellular microRNAs maintain latency of human cytomegalovirus in CD341 progenitors. J Gen Virol. 2011; 92: 1539-1549.
63. Bodaghi B, Jones TR, Zipeto D, Vita C, Sun L, Laurent L et al. Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells. J Exp Med 1998; 188: 855-866.
64. Jenkins C, Abendroth A, Slobedman B. A novel viral transcript with homology to human interleukin-10 is expressed during latent human cytomegalovirus infection. J Virol 2004; 78: 1440-1447.
65. Jenkins C, Garcia W, Godwin MJ, Spencer JV, Stern JL, Abendroth A et al. Immunomodulatory properties of a viral homolog of human interleukin-10 expressed by human cytomegalovirus during the latent phase of infection. J Virol 2008; 82: 3736-3750.
66. Benedict CA, Butrovich KD, Lurain NS, Corbeil J, Rooney I, Schneider P et al. Cutting edge: a novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus. J Immunol 1999; 162: 6967-6970.
67. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501.
68. Ware CF. The TNF superfamily. Cytokine Growth Factor Rev 2003; 14: 181-184.
69. Poole E, King CA, Sinclair JH, Alcami A. The UL144 gene product of human cytomegalovirus activates NFkappaB via a TRAF6-dependent mechanism. EMBO J 2006; 25: 4390-4399.
70. Cheung TC, Humphreys IR, Potter KG, Norris PS, Shumway HM, Tran BR et al. Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway. Proc Natl Acad Sci USA 2005; 102: 13218-13223.
71. Poole E, Atkins E, Nakayama T, Yoshie O, Groves I, Alcami A et al. NFkappaB- mediated activation of the chemokine CCL22 by the product of the human cytomegalovirus gene UL144 escapes regulation by viral IE86. J Virol 2008; 82: 4250-4256.
72. Poole E, Groves I, MacDonald A, Pang Y, Alcami A, Sinclair J. Identification of TRIM23 as a cofactor involved in the regulation of NF-kappaB by human cytomegalovirus. J Virol 2009; 83: 3581-3590.
73. Dumortier J, Streblow DN, Moses AV, Jacobs JM, Kreklywich CN, Camp D et al. Human cytomegalovirus secretome contains factors that induce angiogenesis and wound healing. J Virol 2008; 82: 6524-6535.
74. Fiorentini S, Luganini A, DellOste V, Lorusso B, Cervi E, Caccuri F et al. Human cytomegalovirus productively infects lymphatic endothelial cells and induces a secretome that promotes angiogenesis and lymphangiogenesis through interleukin-6 and granulocyte-macrophage colony-stimulating factor. J Gen Virol 2011; 92: 650-660. Epub 2010/12/03.
75. Noriega VM, Haye KK, Kraus TA, Kowalsky SR, Ge Y, Moran TM et al. Human cytomegalovirus modulates monocyte-mediated innate immune responses during short-term experimental latency in vitro. J Virol 2014; in press.
76. Mason GM, Jackson S, Okecha G, Poole E, Sissons JG, Sinclair J et al. Human cytomegalovirus latency-associated proteins elicit immunesuppressive IL-10 producing CD41 T cells. PLoS Pathog 2013; 9: e1003635.
77. Tey SK, Goodrum F, Khanna R. CD81 T-cell recognition of human cytomegalovirus latency-associated determinant pUL138. J Gen Virol 2010; 91: 2040-2048.
78. Crompton L, Khan N, Khanna R, Nayak L, Moss PA. CD41 T cells specific for glycoprotein B from cytomegalovirus exhibit extreme conservation of T-cell receptor usage between different individuals. Blood 2008; 111: 2053-2061.
79. Marshall NA, Vickers MA, Barker RN. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J Immunol 2003; 170: 6183-6189.
80. Jones M, Ladell K, Wynn KK, Stacey MA, Quigley MF, Gostick E et al. IL-10 restricts memory T cell inflation during cytomegalovirus infection. J Immunol 2010; 185: 3583-3592.
81. Humphreys IR, de Trez C, Kinkade A, Benedict CA, Croft M, Ware CF. Cytomegalovirus exploits IL-10-mediated immune regulation in the salivary glands. J Exp Med 2007; 204: 1217-1225.
82. de Vries JJ, van Zwet EW, Dekker FW, Kroes AC, Verkerk PH, Vossen AC. The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: a population-based prediction model. Rev Med Virol 2013; 23: 241-249.
83. Froberg MK. Review: CMV escapes! Ann Clin Lab Sci 2004; 34: 123-130.
84. Aubert G, Hassan-Walker AF, Madrigal JA, Emery VC, Morte C, Grace S et al. Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J Infect Dis 2001; 184: 955-963.
85. Gratama JW, van Esser JW, Lamers CH, Tournay C, Lowenberg B, Bolhuis RL et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD81 T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001; 98: 1358-1364.
86. Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, Apperley J et al. Direct visualization of cytomegalovirus-specific Tcell reconstitution after allogeneic stem cell transplantation. Blood 2001; 97: 1232-1240.
87. Gandhi MK,WillsMR, Okecha G, Day EK, Hicks R,Marcus RE et al. Late diversification in the clonal composition of human cytomegalovirusspecific CD81 T cells following allogeneic hemopoietic stem cell transplantation. Blood 2003; 102: 3427-3438.
88. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007; 17: 253-276.
89. de Vries JJ, Korver AM, Verkerk PH, Rusman L, Claas EC, Loeber JG et al. Congenital cytomegalovirus infection in the Netherlands: birth prevalence and risk factors. J Med Virol 2011; 83: 1777-1782.
90. Mussi-Pinhata MM, Yamamoto AY, Moura Brito RM, de Lima Isaac M, de Carvalho e Oliveira PF, Boppana S et al. Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clin Infect Dis 2009; 49: 522-528.
91. Krause PR, Bialek SR, Boppana SB, Griffiths PD, Laughlin CA, Ljungman P et al. Priorities for CMV vaccine development. Vaccine 2013; 32: 4-10.
92. Weekes MP, Tan SY, Poole E, Talbot S, Antrobus R, Smith DL et al. Latency-associated degradation of the MRP1 drug transporter during latent human cytomegalovirus infection. Science 2013; 340: 199-202.
93. Murphy JC, Fischle W, Verdin E, Sinclair JH. Control of cytomegalovirus lytic gene expression by histone acetylation. EMBO J 2002; 21: 1112-1120.
94. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014; 124: 30-39.
95. Barton KM, Burch BD, Soriano-Sarabia N, Margolis DM. Prospects for treatment of latent HIV. Clin Pharmacol Ther 2013; 93: 46-56.
96. Kent SJ, Reece JC, Petravic J, Martyushev A, Kramski M, de Rose R et al. The search for an HIV cure: tackling latent infection. Lancet Infect Dis 2013; 13: 614-621.
97. Siliciano JD, Siliciano RF. HIV-1 eradication strategies: design and assessment. Curr Opin HIV AIDS 2013; 8: 318-325.